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Abstract DNA topoisomerase I and II have been shown to be
modi¢ed with a ubiquitin-like protein SUMO in response to
their speci¢c inhibitors called ‘poisons’. These drugs also dam-
age DNA by stabilizing the enzyme^DNA cleavable complex
and induce a degradation of the enzymes through the 26S pro-
teasome system. A plausible link between sumoylation and deg-
radation has not yet been elucidated. We demonstrate here that
topoisomerase IIL, but not its isoform IIK, is selectively de-
graded through proteasome by exposure to the catalytic inhib-
itor ICRF-193 which does not damage DNA. The L isoform
immunoprecipitated from ICRF-treated cells was modi¢ed by
multiple modi¢ers, SUMO-2/3, SUMO-1, and polyubiquitin.
When the SUMO conjugating enzyme Ubc9 was conditionally
knocked out, the ICRF-induced degradation of topoisomerase
IIL did not occur, suggesting that the SUMO modi¢cation path-
way is essential for the degradation.
5 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: Ubiquitin-like protein; SUMO;
DNA topoisomerase II; Proteasome
1. Introduction
Recent studies on post-transcriptional protein modi¢cation
by proteinaceous modi¢ers, ubiquitin and ubiquitin-like pro-
teins (UBLs) have opened an avenue to novel regulatory path-
ways in living cells [1,2]. SUMO (small ubiquitin-like modi-
¢er) is a highly conserved protein in eukaryotes and the most-
studied UBL to date. Although it shares only moderate se-
quence identity with ubiquitin, their conjugation pathways
have extensive similarities. Yeast and invertebrates have a
single SUMO (also called SMT3) but three isoforms, termed
SUMO-1, SUMO-2, and SUMO-3, have been identi¢ed in
vertebrates. The latter two are highly homologous to each
other (94% identity) but diverge signi¢cantly from SUMO-1
(V50% identity). As compared to SUMO-1, much less infor-
mation is available at present on the conjugation partners of
SUMO-2/3. While selective degradation of multi-ubiquiti-
nated proteins by the 26S proteasome has now been estab-
lished, downstream events of sumoylation are less obvious. In
some cases, SUMO modi¢cation occurs at the same lysine
residues that are used for ubiquitination, thus inhibiting mul-
ti-ubiquitination and preventing the protein from degradation
by proteasome [3]. Conversely, modi¢cation by SUMO has
not yet been reported to accelerate protein degradation.
Camptothecin and VM-26, often referred to as topoisomer-
ase poisons, are representative inhibitors of type I (topo I)
and type II (topo II) topoisomerases, respectively. These drugs
bind speci¢cally to each enzyme and stabilize the topo^DNA
covalent intermediates (cleavable complex) by preventing the
religation of transiently cleaved DNA strands [4,5]. ICRF-193
and other bisdioxopiperazines, classi¢ed as ‘catalytic’ inhibi-
tors of topo II, do not interfere with the DNA rejoining step
but bind to the closed-clamp form of the enzyme^ATP com-
plex to trap the DNA strands topologically between the di-
meric subunits [6]. It has been shown that topoisomerases
undergo proteasome-mediated degradation in cells treated
with topo poisons [7,8]. Since poisoned cells eventually gen-
erate enzyme-linked DNA double strand breaks that are toxic
to cells [9], the induced reduction of enzyme level was thought
to be a cellular defense mechanism [10].
Two isoforms of topo II, K and L, are present in vertebrates
that are encoded by separate genes [11], whereas only one
form is present in lower eukaryotes including the budding
yeast Saccharomyces cerevisiae, in which sumoylation of
topo II is involved in the control of centromeric chromatid
cohesion [12]. Although topoisomerase inhibitors have been
reported to induce sumoylation of both topo I and topo II
[13,14], its biological signi¢cance remains largely unknown.
These observations suggest a connection between sumoylation
and degradation but this conjecture has not been fully tested.
In the present communication, we demonstrate that topo IIL
is selectively degraded via proteasome by exposure to ICRF-
193, a catalytic inhibitor which does not damage DNA, and
that protein modi¢cation by SUMO can be an early signal for
the degradation.
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2. Materials and methods
2.1. Chemicals and antibodies
The following chemicals were obtained from the suppliers indicated
in parentheses: ICRF-193 (Funakoshi), VP-16 (gift from Nippon
Kayaku), MG132 (Calbiochem), camptothecin, leptomycin B and
doxycycline hydrochloride (Sigma). Most compounds were dissolved
in dimethyl sulfoxide, and stored at 320‡C in small aliquots. S7
nuclease, protease inhibitor cocktail, and protein G-Sepharose were
purchased from TaKaRa, Sigma, and Amersham Pharmacia Biotech,
respectively.
Mouse monoclonal antibodies against human topo IIK (4E12) and
topo IIL (3B6) were prepared as described previously [15], and used
for both Western blotting and immunoprecipitation experiments. 3B6
was cross-reactive with rat and chicken antigens. Rabbit polyclonal
antibody to SUMO-1 (FL-101) was purchased from Santa Cruz Bio-
tech. The anti-SUMO-2/3 polyclonal antibody was prepared as de-
scribed [16]. Mouse monoclonal antibodies against polyubiquitin
(FK2) and Ubc9 (N-15) were obtained from A⁄nity Research Prod-
ucts and Santa Cruz Biotech, respectively. IgG prepared from the
serum of a progressive systemic sclerosis patient was used for anti-
DNA topoisomerase I antibody. Anti-matrin 3 antibody was prepared
from a rabbit immunized with a synthetic peptide.
2.2. Cell culture
HeLa cells were cultured in a humidi¢ed atmosphere of 5% CO2 at
37‡C in DMEM medium supplemented with 5% fetal calf serum
(FCS) and 100 Wg/ml kanamycin. Cerebellar granule cells were pre-
pared from the cerebellum of 8-day-old Wistar rats and processed for
primary culture as described previously [15]. Wild type DT40 cells and
Ubc93=3=3tetUbc9 cells were cultured at 39.5‡C under 5% CO2 in
RPMI 1640 supplemented with 10% heat-inactivated FCS plus 1%
chicken serum and 60 Wg/ml kanamycin [17].
2.3. Western blotting
Subcon£uent HeLa cells or cerebellar granule cells at culture day 3
were treated as described in the ¢gure legends. After treatments, cells
were lysed in sodium dodecyl sulfate^polyacrylamide gel electropho-
resis (SDS^PAGE) sample bu¡er (50 mM Tris^HCl: pH 6.8, 2 mM
EDTA, 1% SDS, 1% 2-mercaptoethanol, 8% glycerol, and 0.025%
bromophenol blue) added directly into culture dishes. Samples were
sonicated brie£y and boiled for 2 min before being subjected to elec-
trophoresis. In the experiments where VP-16 or camptothecin was
used, lysates were prepared by the alkali lysis procedure followed by
digestion with S7 nuclease as described [7]. Samples were run in either
6% homogeneous or 2^15% gradient polyacrylamide gels, transferred
onto polyvinylidene di£uoride or nitrocellulose membranes by electro-
blotting, and processed for immunodetection with appropriate ¢rst
and second antibodies according to a standard procedure. Detection
of membrane-bound antibodies was done using an ECL kit (Amer-
sham Pharmacia Biotech). Developed ¢lms were scanned for densito-
metric quanti¢cation of protein bands. When successive detection
with di¡erent antibodies was attempted, the bound antibodies were
stripped o¡ the membrane each time by shaking the membrane in the
antibody stripping bu¡er (2% SDS, 100 mM 2-mercaptoethanol,
62.5 mM Tris^HCl, pH 6.8) at 60‡C for 30 min.
2.4. Immunoprecipitation
Drug-treated cells were lysed in RIPA bu¡er (50 mM Tris^HCl, pH
7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and
0.1% SDS) containing 2% protease inhibitor cocktail, at 4U106 cells/
ml. Cell lysates were vortexed, sonicated brie£y, left on ice for 30 min,
and then spun at 14 000 rpm for 10 min at 4‡C. After pre-clearing the
supernatants (1 ml) with 50 Wl of 50% protein G-Sepharose slurry, the
same volume of protein G-Sepharose that had been pre-coated with
10 Wg of anti-topo IIL monoclonal IgG was added, and incubated
with gentle rotary mixing at 4‡C for 1 h. The suspension was centri-
fuged at 6000 rpm for 1 min, and the sedimented beads were washed
three times with RIPA bu¡er. Immunoprecipitates were resuspended
in SDS^PAGE sample bu¡er, boiled for 2 min, and subjected to elec-
trophoresis.
3. Results
3.1. ICRF-193 induces proteasome-mediated degradation of
DNA topoisomerase IIL in di¡erent cell types
We have shown previously that topo IIL, highly expressed
in cerebellar granule neurons di¡erentiating in vitro, is in-
volved in the transcriptional induction of a subset of genes
that are essential for mature neuronal functions [15]. In that
study, we used the catalytic inhibitor ICRF-193 to suppress
the activity of topo IIL and found unexpectedly that the ex-
pression of topo IIL was markedly reduced in the treated cells.
Subsequent experiments have indicated that the reduction of
topo IIL is not accounted for by suppression of transcription
or translation but is due to a speci¢c degradation via the
proteasome (data not shown).
Since granule cells cultured in vitro do not express topo IIK
[15], we used HeLa cells, in which both topo II isoforms are
expressed, to examine whether topo IIK is also a¡ected by
ICRF-193. A signi¢cant reduction in the topo IIL amount
was evident after the treatment with both topo II inhibitors,
VP-16 (a topo poison) and ICRF-193, whereas topo IIK was
not a¡ected at all under these conditions (Fig. 1A). Levels of
topo I or a protein associated with nuclear matrix (matrin 3)
did not change by the treatment. As in granule cells, the
ICRF-induced reduction in topo IIL represented its degrada-
tion by proteasome which is susceptible to MG132 (Fig. 1B).
Thus, the e¡ect of ICRF-193 on topo IIL degradation is very
similar to that of VM-26 [8]. Because components of the pro-
teasome system are present in both cytoplasm and nucleus
[18], cells were treated with a nuclear protein export inhibitor,
leptomycin B (LMB), to see whether topo IIL degradation
occurs after export to the cytoplasm. LMB had little e¡ect
on the degradation, indicating that topo IIL is degraded by
nuclear proteasome (Fig. 1B).
Fig. 1. Selective degradation of topo IIL in HeLa cells treated with
ICRF-193 and e¡ects of inhibitors. A: Selective down-regulation of
topo IIL by topo II-speci¢c inhibitors with di¡erent action mecha-
nisms. Cell lysates prepared by alkaline solution from HeLa cells in-
cubated for 2 h with topo II-speci¢c inhibitors, 100 WM VP-16 or
10 WM ICRF-193, were treated with S7 nuclease and then subjected
to Western blotting using antibodies against the proteins indicated.
B: E¡ects of inhibitors on the ICRF-induced down-regulation of
topo IIL. HeLa cells were treated with the drugs indicated at the
top for 1 h, in the presence (+) or absence (3) of 10 WM ICRF-
193. These drugs were added 30 min before the addition of ICRF-
193. Concentrations used: 20 WM, MG132; 10 ng/ml, LMB. Cell ly-
sates were subjected to Western blotting to quantify topo IIL. Den-
sitometric values from ¢lm scanning were normalized to those of
matrin 3, as an internal standard, whose expression level remained
constant. Measurements were done on triplicate samples from sepa-
rate dishes and were averaged. Amounts relative to the untreated
control are shown with error bars.
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Granule cells in primary culture are terminally di¡erentiat-
ing without further proliferation whereas HeLa cells are pro-
liferating cells. Although the ICRF-induced topo IIL degra-
dation occurs in both cell types, the rate of degradation
appears to di¡er signi¢cantly. A time course analysis revealed
that topo IIL degrades much faster in HeLa cells compared to
granule cells (Fig. 2). The degradation appeared to proceed in
two phases, rapid and slow. The half-degradation time (t1=2)
for the rapid phase was 10 min and 53 min in HeLa cells and
granule cells, respectively.
3.2. Multiple modi¢cation of DNA topo IIL in granule cells
treated with ICRF-193
We used granule cells to analyze the modi¢cation status of
topo IIL for the following reasons. Unlike in HeLa cells, the
modi¢ed forms of topo IIL are readily identi¢able in granule
cells. The slower time course of topo IIL degradation in gran-
ule cells is also advantageous to discriminate the chain of
events. Topo IIL immunoprecipitates prepared at various
times of incubation with ICRF-193 were separated in a gra-
dient gel to attain a better resolution in the high-molecular-
weight region. After blotting, the same membrane was probed
with antibodies to topo IIL, SUMO-2/3, SUMO-1, and poly-
ubiquitin. These antibodies revealed a ladder of discrete bands
overlying on smears (Fig. 3). The bands right above the topo
IIL band that are detected with anti-SUMO-2/3 antibody ap-
peared ¢rst as early as after 5 min of ICRF treatment and
decreased after 15 min. Bands reactive to anti-SUMO-1 in-
creased abruptly at 15 min and continued to increase after-
wards. The smearing polyubiquitinated bands followed a sim-
ilar time course although they reached a higher molecular
weight region. It should be noted that these smears are hardly
discernible in the top panel (topo IIL) because of the much
lower epitope density. Since the anti-ubiquitin antibody used
here reacts speci¢cally with polymerized ubiquitin, the modi-
¢ed topo IIL detected by the antibody is likely to be targeted
directly to proteasome.
Fig. 2. Di¡erential time course of topo IIL degradation in HeLa
cells and granule cells. Cultured cells treated with ICRF-193 were
lysed at increasing time points and subjected to Western blotting to
detect topo II isoforms (shown in insets). Band densities were quan-
ti¢ed by densitometry and the data relative to zero time were plot-
ted against incubation time. A: HeLa cells treated with 10 WM
ICRF-193. Open circles, topo IIK ; closed circles, topo IIL. Time
points shown in the inset are 0, 5, 15, 30, 45, 60, and 90 min. t1=2
for the rapid phase of topo IIL degradation was estimated from a
semi-logarithmic plot. B: Granule cells treated with 30 WM ICRF-
193. Closed circles designate topo IIL. Time points shown in the in-
set are 0, 5, 15, 30, 60, 120, 360, and 720 min. Note that the upper
band (marked by the asterisk) already appears after 5 min of treat-
ment.
Fig. 3. Distinct modi¢cation patterns of topo IIL in granule cells
treated with ICRF-193. Granule cells treated with 30 WM ICRF-193
were lysed with RIPA bu¡er at increasing time points and subjected
to immunoprecipitation with anti-topo IIL antibody. Immunopreci-
pitates were run in SDS^PAGE gradient gel, and then subjected to
Western blotting to detect the proteins indicated on the left with
corresponding antibodies. The same membrane was used throughout
by stripping o¡ antibodies between detections (see Section 2). Modi-
¢ed protein bands in the high-molecular-weight region are labeled
on the right (arrows). The unmodi¢ed topo IIL band is indicated by
arrowheads. Incubation times are shown at the top.
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3.3. The SUMO conjugating enzyme Ubc9 is essential for the
degradation of DNA topo IIL
Ubc9 is the only enzyme identi¢ed so far to conjugate
SUMO isoforms to target proteins [19]. To test whether su-
moylation is an essential modi¢cation for ICRF-induced topo
IIL degradation, we used a mutant chicken DT40 cell line
which lacks the endogenous Ubc9 gene but contains a Ubc9
transgene under the control of a tetracycline-repressible pro-
moter (Ubc93=3=3tetUbc9 cells). When the Ubc9 mutant cells
were treated with doxycycline for 2 days, Ubc9 expression was
reduced markedly as expected, and abolished completely after
3 days (Fig. 4). The sumoylated proteins detected by anti-
SUMO-1 antibody started to decrease later and became al-
most undetectable on day 4 of doxycycline treatment, includ-
ing the 90 kDa protein which is most likely RanGAP1 modi-
¢ed by SUMO-1 [20]. These results are consistent with the
original character of Ubc93=3=3tetUbc9 cells reported previ-
ously [17].
Wild type DT40 cells and Ubc93=3=3tetUbc9 cells cultured
for 4 days in the presence or absence of doxycycline were next
treated with ICRF-193 and levels of topo IIL or sumoylated
proteins were determined by immunoblotting (Fig. 5A). In
wild type DT40 cells, as in HeLa cells and granule cells,
ICRF-193 induced degradation of topo IIL with a concomi-
tant increase in the high-molecular-weight proteins recognized
by antibody to SUMO-1. The topo IIL degradation was also
susceptible to MG132 (not shown). In doxycycline-treated
Ubc93=3=3tetUbc9 cells, however, ICRF-193 induced neither
topo IIL degradation nor an increase in sumoylated proteins.
The result was con¢rmed by densitometric quanti¢cation us-
ing triplicate samples (Fig. 5B). To see whether the ubiquitin^
proteasome pathway is intact in the absence of Ubc9 expres-
sion, the camptothecin-induced degradation of topo I was
examined (Fig. 5C). The induced reduction of topo I, which
was suppressed by MG132, occurred to the same extent even
Fig. 4. Down-regulation of Ubc9 and sumoylation in a Ubc9-de¢-
cient chicken DT40 cell line containing an exogenous Ubc9 gene
that can be turned o¡ by doxycycline. The mutant cells
(Ubc93=3=3tetUbc9) were incubated in the presence (+) or absence
(3) of 10 ng/ml doxycycline (Dox) for the days indicated, and the
expression of Ubc9 or proteins modi¢ed with SUMO-1 was ana-
lyzed by Western blotting using speci¢c antibodies. Positions of
topo IIL (arrowhead), RanGAP1 (arrow), and molecular size
markers are indicated.
Fig. 5. Ubc9 is essential for the degradation of topo IIL induced by
ICRF-193. A: After incubating the wild type DT40 cells (wt) or
Ubc93=3=3tetUbc9 cells (mutant) in the presence (+) or absence (3)
of 10 ng/ml doxycycline for 4 days, cells were incubated with (+) or
without (3) 10 WM ICRF-193 for 2 h. Levels of topo IIL and su-
moylated proteins were analyzed by Western blotting using speci¢c
antibodies. B: Three independent reactions were done under the
same experimental conditions shown above. After normalization to
an internal standard, densitometric readings for topo IIL from tripli-
cate samples were averaged and the amounts relative to untreated
controls are shown with error bars. C: Ubc93=3=3tetUbc9 cells
treated as above were incubated for 4 h in the presence (+) or ab-
sence (3) of 25 WM camptothecin (CPT). MG132 (30 WM) was
added 30 min prior to the start of incubation. Cell lysates were pre-
pared by the alkali lysis procedure followed by S7 nuclease diges-
tion and then topo I was detected by Western blotting.
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in the presence of doxycycline, indicating that the proteolytic
system itself is still unimpaired under these conditions. There-
fore, it is now clear that sumoylation is a prerequisite for
ICRF-induced topo IIL degradation.
4. Discussion
We have shown in the present study that topo IIL degra-
dation can be induced by the catalytic inhibitor ICRF-193
which does not damage DNA. Since the topo II protein clamp
on DNA induced by the drug could be an obstacle against
various DNA transactions, the same consequence, namely the
accelerated degradation that is caused by topo II poisons,
may be expected also for catalytic inhibitors. A similar obser-
vation was made by others recently [21].
The ICRF-induced multiple modi¢cation of topo IIL ap-
peared to occur in a cascade-like manner (Fig. 3). SUMO-2/
3 conjugation may be particularly important because it pre-
ceded that of SUMO-1 and polyubiquitin. Consistent with
this view is a rapid and extensive conjugation of SUMO-2/3
to high-molecular-weight proteins following various protein-
damaging stresses such as high temperature, oxidative agent,
and ethanol [16]. It is an interesting possibility that SUMO-2/
3 conjugation to denatured proteins somehow triggers subse-
quent events toward their disposal through the proteasome
system. Unlike SUMO-1, SUMO-2/3 has a consensus motif
for autosumoylation and can form polymeric chains on pro-
tein substrates [22]. Formation of heteromultimers of di¡erent
SUMO isomers is also feasible, where SUMO-1 may serve as
a chain terminator. Whether topo IIL is modi¢ed by poly-
meric chains of SUMO or whether the same molecule of
topo IIL is simultaneously modi¢ed with SUMO and ubiqui-
tin remains to be shown. The SUMO moiety might be re-
moved by deconjugating isopeptidase before ubiquitination
as suggested by the transient nature of SUMO-2/3 conjugates
(Fig. 3).
Analysis of Ubc9-de¢cient DT40 cells demonstrated unam-
biguously that SUMO modi¢cation is essential for ICRF-in-
duced degradation of topo IIL (Fig. 5). Although our data do
not exclude the possible involvement of other sumoylation
targets, the selective degradation of topo IIL may imply that
potential sumoylation sites are di¡erent between topo II iso-
forms. The topo IIL^inhibitor^DNA ternary complex may be
a preferential target of Ubc9. Whether SUMO conjugation
facilitates the dissociation of topo IIL clamps from DNA is
still unclear. An interesting discovery in this regard is that the
a⁄nity of thymine-DNA glycosylase to abasic site DNA is
signi¢cantly reduced when the enzyme is modi¢ed by both
SUMO-1 and SUMO-2/3, resulting in an increased enzymatic
turnover [23]. In contrast to topo IIL, it appears that SUMO
modi¢cation plays little role in camptothecin-induced topo I
degradation which occurs independent of Ubc9 (Fig. 5C).
This is consistent with the previous report showing that
the rate of degradation was not altered even when all the
major sumoylation sites of topo I were disrupted by mutation
[24].
As for the relationship between sumoylation and ubiquiti-
nation, our results imply that these modi¢cations are cooper-
ating, instead of antagonizing [3], to direct the stalled topo IIL
to destruction via proteasome, suggesting a possible cross-talk
between these pathways in the repair of damaged chromatin.
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